There was little evidence of co-localisation for these findings, a necessary precondition to infer causality between PPARG perturbation and these cancer endpoints, possibly reflecting either the absence of shared causal variants across type 2 diabetes liability and these cancer endpoints in PPARG or the low statistical power of these analyses. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.